Application of different high-risk human papillomavirus detection methods in cervical lesion screening

Abstract

Objective To investigate clinical applications of hybrid capture (HC)2 and Cervista methods to detect high-risk human papillomavirus (HR-HPV) in cervical lesion screening. Methods From January 1 to December 31, 2015, a total of 155 women who underwent cervical ThinPrep liquid-based cytology test (TCT) screening and two other HR-HPV detection methods (HC2 and Cervista methods) simultaneously in the Department of Gynecological Oncology Clinic at Beijing Obstetrics and Gynecology Hospital, Capital Medical University, were chosen as study subjects. The positive rate of HR-HPV detection by HC2 and Cervista methods were compared. This research was in line with ethics standards promulgated by the ethical review committee of the Beijing Obstetrics and Gynecology Hospital, Capital Medical University, which had been approved by the committee. Results ①In 155 subjects, the crude coincidence rate of HR-HPV positive rates between HC2 and Cervista methods was 72.9% (113/155). The sensitivity of Cervista method in detection of HR-HPV infection was 52.9% (82/155), specificity was 20.0% (31/155), and Kappa value was 0.40. ② The positive rates of HC2 method was significantly correlated with the severity of cervical cytology (rs=0.98, P=0.01), but the positive rates of Cervista method was not correlated with the severity of cervical cytology (rs=0.49, P=0.33). ③ The area under curve (AUC) of receiver operating characteristic (ROC) of HR-HPV infection detected by HC2 method was 0.85 (95%CI: 0.79-0.91, P<0.001). Taking the maximum Youden index (YI) as principle, the best critical value of HR-HPV detected by HC2 method was 19.61 RLU/CO, and at that point the sensitivity was 71.6%, specificity was 88.3%. Conclusions HC2 and Cervista methods can not replace each other. Using HC2 and Cervista HR-HPV screening at the same time can improve the detection rate of HR-HPV. Key words: Human papillomavirus; Uterine cervical neoplasms; ROC curve; ThinPrep liquid-based cytology test; Women